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ABBREVIATIONS AND ACRONYMS 
95% CI = 95% Confidence Intervals 
ACS = Acute Coronary Syndromes 
CABG = Coronary Artery Bypass Graft 
CAD = Coronary Artery Disease 
IHD = Ischemic Heart Disease  
ISACS-TC = International Survey of Acute Coronary Syndromes in Transitional Countries 
IQR = Interquartile Percentile Range  
LAD = Left Anterior Descending Artery 
MI = Myocardial Infarction  
OR = Odds Ratio 
PCI = Percutaneous Coronary Intervention 
RCA = Right Coronary Artery 
SD = Standard Deviation 
STEMI = ST- Segment Elevation Myocardial Infarction  
TIMI = Thrombolyisis In Myocardial Infarction 
UFH = Unfractioned Heparin  
VT/VF = Ventricular Tachycardia/ Ventricular Fibrillation 
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ABSTRACT 
No-reflow occurring during percutaneus coronary intervention (PCI) has been associated with 
poor outcomes. The objectives of this study were to evaluate the incidence of no-reflow as 
independent predictor of adverse events and to assess whether baseline pre-procedural 
treatment options may affect clinical outcomes. Data were derived from the International 
Survey of Acute Coronary Syndromes in Transitional Countries (NCT01218776) registry, a 
prospective survey of patients presenting with ACS over a 5-year period (January 2010 to 
January 2015). Data were prospectively collected from 5997 patients undergoing PCI, 
identifying those with no-reflow, and analyzed their treatments and clinical outcomes. No-
reflow was defined as post-PCI TIMI flow grade 0-1, in the absence of post-procedural 
significant (≥ 25%) residual stenosis, abrupt vessel closure, dissection, perforation, thrombus 
of the original target lesion, or epicardial spasm. The outcome measure was in-hospital 
mortality. No-reflow was identified in 128 of 5997 patients who have undergone PCI (2.1%). 
On multivariate analysis, patients with no-reflow were more likely to be older (OR: 1.20, 95% 
CI: 1.01 – 1.44) and to be admitted with a diagnosis of ST-elevation myocardial infarction 
(OR: 2.96, 95% CI: 1.85 – 4.72). No-reflow was highly predictive of in-hospital mortality 
(17.2% vs. 4.2%, P <0.001) and remained a significant independent predictor of death after 
adjustment for demographic and clinical variables (OR: 4.60, 95% CI: 2.61 – 8.09). 
Multivariable regression analysis was also performed to identify independent relationship 
between pre-procedural treatment regimens, angiographic characteristics and no-reflow 
phenomenon. Administration of pre-procedural unfractioned heparin, showed a strong inverse 
predictive value in terms of post-PCI TIMI flow and no-reflow phenomenon (OR: 0.65, 95% 
CI: 0.43 – 0.99). Similarly, a 600 mg loading dose of clopidogrel showed a trend associated 
with a reduction in the likehood of no-reflow (OR: 0.61, 95% CI: 0.37 – 1.00). Aspirin, 
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enoxaparin, 300 mg loading dose of clopidogrel, did not significantly impact the occurrence 
of the no-reflow. Angiographic characteristics associated with no-reflow phenomenon were 
coronary stenosis severity ≥ 50% of the right coronary artery, presence of multivessel 
coronary disease and pre - procedural TIMI blood flow grade 0-1. In conclusion, no-reflow 
during PCI is a strong independent predictor of in-hospital mortality. Pre-procedural 
administration of 600 mg loading dose of clopidogrel and/or unfractioned heparin is 
associated with reduced incidence of no-reflow. 
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INTRODUCTION  
Successful coronary revascularization does not always lead to coronary reperfusion. There is a 
group of patients who do not benefit from prompt restoration of antegrade flow, as they fail to 
show resolution of chest pain and electrocardiographic (ECG) changes suggestive of 
ischemia.  These patients present an angiographic phenomenon characterized by the evidence 
of no-flow (Thrombolysis in Myocardial Infarction [TIMI] flow equal to or less than 1) in the 
affected vessel despite the  absence of post-procedural significant (≥ 25%) residual stenosis, 
flow-limiting dissection, perforation, coronary spasm, or in-situ thrombosis [1]. No-reflow 
occurring during percutaneus coronary intervention (PCI) has been associated with poor 
prognosis [2-7]. 
The no-reflow phenomenon is still poorly understood. Although atherothrombotic 
microembolization appears to be an important contributor to no reflow, particularly in the 
setting of primary PCI for acute myocardial infarction [8], other explanation has been 
suggested including vascular dysfunction due to an over-activation of alpha-adrenergic 
induced vasoconstriction [9]. As a consequence selection of therapy is still under scrutiny. 
Therapy depends critically on an underlying model of the disease process, because only the 
pathophysiology of the disease may suggest a method for its treatment, and knowledge about 
the pathophysiology of no-reflow is still rudimentary.  
Clinical knowledge about the no-reflow phenomenon has been based mainly on small cohort 
studies. In addition most of these studies are dated.  Thus little is known about its incidence 
and the factors that up-to-date may predispose to its development among patients with ACS 
undergoing PCI. The objective of the current study was to evaluate in a large registry cohort 
of contemporary patients the incidence of no-reflow as independent predictor of adverse 
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events and to assess whether baseline pre-procedural treatment options may affect clinical 
outcomes. 
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MATERIALS AND METHODS  
Data collection  
Data collection and analysis for the International Survey of Acute Coronary Syndromes in 
Transitional Countries (ISACS-TC; ClinicalTrials.gov Identifier: NCT01218776) registry has 
been previously described [10-20]. In brief, patients were eligible for inclusion if they met the 
following criteria: age ≥ 18 years, symptoms consistent with acute cardiac ischemia, 
documented evidence of new or presumed new significant ST-segment–T wave (ST–T) 
changes or new left bundle branch block on serial electrocardiograms and/or elevated 
biomarkers of myocardial necrosis according to universal standardized criteria [21]. The 
network is constituted of 29 tertiary and 28 secondary hospitals in Eastern Europe. All 
hospitals had intensive coronary care units, and medical reperfusion therapy. The tertiary 
hospitals had cardiac catheterization facilities. The study was approved by the local research 
ethics committee from each participating hospital.  
Participants  
Six thousand six patients undergoing PCI, for ST-segment elevation myocardial infarction 
(STEMI) and non ST-segment elevation ACS included the ISACS-TC hospitals from January 
2010 to January 2015 were analyzed, identifying those with no-reflow phenomenon, and 
analyzed their treatments, angiographic features and clinical outcomes. After excluding 9 
patents with missing data on post-PCI TIMI blood flow grades, the final study population 
consisted of 5997 patients with full records on post-PCI TIMI blood flow grades. 
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Definitions 
No-reflow phenomenon was defined as post-PCI TIMI blood flow grade 0-1 (in the absence 
of post-procedural residual stenosis ≥ 25%, abrupt vessel closure, dissection, perforation, 
thrombus of the original target lesion, or epicardial spasm) [1].  
Minor bleeding was defined as any clinically sign of haemorrhage associated with a fall in 
haemoglobin 5 ≤ g/dl occurred during hospitalization. Major bleeding was defined as any 
clinically sign of haemorrhage associated with a fall in haemoglobin 5 > g/dl or ay 
intracranial bleeding occurred during hospitalization [22-24].   
Measures of outcomes 
The primary endpoint was in-hospital mortality. Secondary endpoints were to evaluate 
baseline clinical characteristics, pre-procedural treatment options and angiographic 
characteristics that may predict no-reflow phenomenon. Other outcomes of interest were the 
incidence of stroke, ventricular tachycardia and/or ventricular fibrillation, minor and major 
bleeding during hospitalization.   
Statistical analysis 
Baseline and angiographic characteristics of the patients were compared by Students t-test or 
Kruskal-Wallis rank-sum test for continuous variables and Pearson’s χ2 test for categorical 
variables, as appropriate. Results are presented as percentages for categorical variables, mean 
± standard deviation (SD) or median and interquartile percentile range (IQR) for continuous 
variables. Kaplan - Meier curve estimates were calculated for mortality rates. Mortality rates 
are shown as proportion and 95% confidence intervals (95% CI). Log-rank test was used to 
compare event rates among the two patients groups. 
Multivariable logistic regression analysis was performed in order to identify the independent 
predictors of in-hospital mortality in patients presenting the no-reflow phenomenon as 
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compared to patients without no-reflow during PCI. Another multivariable logistic regression 
analysis was performed to identify the independent predictors of no-reflow phenomenon.  
Results are presented as odds ratios (OR) and 95% CI. Constant covariates included in the 
analyses were: sex; age; cardiovascular risk factors: (history of hypercholesterolemia, history 
of diabetes, history of hypertension, smoking status); clinical history of ischemic heart disease 
(previous myocardial infarction, previous PCI, and previous coronary artery bypass graft) 
clinical history of cardiovascular disorders (previous peripheral artery disease, and previous 
stroke and/or previous transient ischemic attack) and severity of clinical presentation (STEMI, 
Killip Class ≥ 3, systolic blood pressure and heart rate). Secondary analyses were performed 
to identify independent relationship between pre-procedural treatment regimens, angiographic 
characteristics and no-reflow phenomenon. Covariates introduced in the secondary analyses, 
as dummy variables, were use of aspirin, clopidogrel, unfractioned heparin, enoxaparin, 
coronary stenosis severity ≥ 50% and baseline TIMI blood flow grade 0-1. A C-index (area 
under the receiver-operator characteristic curve) was generated for each regression models to 
measure the concordance. For all analyses, statistical significance was defined as a value of P 
< 0.05. Statistical evaluation was performed using STATA 11 (StataCorp. College Station, 
TX, USA). 
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RESULT 
Among 5997 patients with ACS, 128 (2.1%) developed no-reflow phenomenon during PCI. 
Median hospital stay was 6 days. Overall there were 271 (4.5%) patients who died during 
hospitalization.  
Table 1. Baseline characteristics  
Characteristics 
No-reflow phenomenon  
Yes 
N=128 
No 
N=5869 
P value 
Age (years) 63.7 ± 11.6 61.2 ± 11.5 0.01 
Women  32.0 29.7 0.57 
History of diabetes mellitus 27.1  24.6 0.53 
History of hypercholesterolemia  52.7 37.3 0.001 
History of hypertension  71.1 69.1 0.62 
Family history of CAD 18.1 25.4 0.07 
Current smoking 44.3 40.6 0.40 
History of MI 14.8 17.0 0.52 
History of PCI  5.5 8.0 0.28 
History of CABG  0.8 1.7 0.44 
History of IHD* 17.2 20.0 0.43 
History of cardiovascular disordersǂ  7.8 4.3 0.05 
Clinical presentation     
Systolic blood pressure at baseline (mmHg) 140.9 ± 22.9 145.3 ± 24.5 0.04 
Heart rate at baseline (bpm) 82.5 ± 22.3 81.3 ± 17.9 0.48 
Serum creatinine at baseline (μmol/L) 104.6 ± 6.7 93.1 ± 1.5 0.29 
STEMI  75.8 53.8 <0.001 
Killip class ≥ 3  5.5 2.2 0.01 
Door to balloon time, min (IQR) 44.5 [28 - 75] 45 [30 - 83] 0.45 
Time from symptoms onset to admission <12 hrs 74.4 77.6 0.39 
Medications     
Aspirin  98.4 98.8 0.69 
Clopidogrel loading dose 600 mg vs. 300 mg 65.7 75.7 0.01 
UFH 59.8 73.7 <0.001 
Enoxaparin 44.4 34.9 0.02 
Hospital stay, days (IQR) 6 [3 - 8] 5 [3 - 7] 0.50 
In-hospital mortality  17.2 4.2 <0.001 
Data are presented as percentages (%), mean ± SD or median (interquartile range [IQR]) 
*History of IHD: history of MI and/or history of PCI and/or history of CABG 
ǂHistory of cardiovascular disorders: history of previous transient ischemic attack and/or previous stroke and/or 
peripheral artery disease.  
CAD indicates coronary artery disease; MI, myocardial infarction; PCI, percutanous coronary intervention; CABG, 
coronary artery bypass graft; IHD, ischemic heart disease; STEMI, ST-segment elevation myocardial infarction; 
UFH, unfractioned heparin. 
 Patient characteristics 
The baseline characteristics for the no
Patients with no-reflow were more likely to be older and to have a history of 
hypercholesterolemia. They were more likely to present with pulmonary oedema and/or 
cardiogenic shock (Killip Class 
administration of pre-procedural antithrombotic medications, namely
mg of clopidogrel and unfra
Biomarkers of myocardial necrosis that can predict infract size were significan
the no-reflow group (creatine kinase 
troponin: mean 11.1 versus 6.8 
significantly higher for patients developing no
0.001) (Table 1 and Figure 1
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coronary disease of the right coronary artery and impaired baseline TIMI blood flow grade as 
compared to patients without no-reflow. Patients developing no-reflow were more likely to 
undergo PCI through the transfemoral approach. They were less likely to be stented with 
either bare metal stents or drug eluting stents.  
Table 2. Angiographic characteristics 
Characteristics 
No reflow phenomenon  
Yes 
N=128 
No 
N=5869 
P-value 
Trans radial approach  37.4 72.1 <0.001 
Left main stenosis ≥ 50% 5.6 6.5 0.71 
LAD stenosis stenosis ≥ 50% 69.0 62.1 0.15 
Circumflex artery stenosis ≥ 50% 43.2 40.1 0.66 
RCA stenosis ≥ 50% 75.5 61.2 0.004 
Multivessel CAD  73.0 53.8 <0.001 
Bifurcation lesion 7.8 6.2 0.44 
Previously treated lesion  4.7 5.4 0.73 
Baseline TIMI flow grade 0-1 vs. 2-3 93.9 57.4 <0.001 
Reference diameter, mm  3.2  ±  0.7 3.4  ±  5.8 0.91 
Lesion length, mm  18.8  ± 11.3 19.2  ± 8.7 0.90 
Stent apposition 71.0 94.6 <0.001 
Data are presented as percentages (%) or mean ± SD, unless otherwise stated.  
LAD indicates Left anterior descending artery; CAD, coronary artery disease; RCA, Right coronary artery TIMI, 
Thrombolysis In Myocardial Infarction  
Factors associated with in-hospital mortality  
On multivariate analysis (Table 3), no-reflow phenomenon, older age, history of diabetes 
mellitus, history of ischemic heart disease, history of cardiovascular disorders, increased heart 
rate at admission, STEMI as index event and Killip Class ≥ 3 were independently associated 
with in-hospital mortality. Conversely, a history of hypertension or hypercholesterolemia and 
higher systolic blood pressure levels at presentation were associated with lower adjusted 
mortality rates.  
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 In-hospital complications  
With the exception of stroke and life threatening arrhythmias, which occurred more frequently 
in patients developing no-reflow, in-hospital complications did not differ between patient 
groups (Figure 2). 
 
Figure 2. In-hospital complications 
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Table 3. Characteristics independently associated with in-hospital mortality  
Variable OR 95% CI P Value 
No-reflow phenomenon  4.60 2.61 – 8.09 <0.001 
Age (per 10 years increase) 1.59 1.39 – 1.83 <0.001 
Women  1.13 0.83 – 1.54 0.40 
History of diabetes mellitus   1.61 1.19 – 2.19 0.002 
History of hypertension  0.70 0.51 – 0.97 0.03 
History of hypercholesterolemia   0.52 0.37 – 0.73 <0.001 
Current smoking  1.08 0.78 – 1.49 0.63 
History of IHD  1.50 1.06 – 2.12 0.02 
History of cardiovascular disorders  2.24 1.35 – 3.71 0.002 
Heart rate at baseline (per 1 SD increase)* 1.16 1.04 – 1.30 0.005 
Systolic blood pressure at baseline (per 1 SD increase)* 0.68 0.59 – 0.77 <0.001 
STEMI 1.78 1.30 – 2.43 <0.001 
Killip Class ≥ 3 5.93 3.49 – 10.07 <0.001 
C statistics: 0.78 
Incidence of in-hospital mortality in the overall study population: n=271 (4.5%).  
*SDs for heart rate and systolic blood pressure are 17.5 b.p.m and 23.1 mmHg 
IHD indicates ischemic heart disease; STEMI, ST-segment elevation myocardial infarction; SD, standard 
deviation  
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Factors associated with no-reflow phenomenon  
Predictors of no-reflow phenomenon are shown in Table 4. Older age, history of 
hypercholesterolemia and STEMI at presentation were independently associated with the 
development of no-reflow phenomenon during PCI.  
Table 4. Predictors of No-Reflow Phenomenon  
Variable OR 95% CI P Value 
Age (per 10 years increase) 1.20 1.01 – 1.44 0.04 
Women  1.15 0.75 – 1.75 0.50 
History of diabetes mellitus   1.06 0.68 – 1.66 0.78 
History of hypertension  0.98 0.63 – 1.54 0.95 
History of hypercholesterolemia   1.95 1.31 – 2.91 0.001 
Current smoking  1.11 0.73 – 1.68 1.68 
History of IHD  0.72 0.42 – 1.25 0.25 
History of cardiovascular disorders  1.81 0.88 – 3.73 0.10 
Heart rate at baseline (per 1 SD increase)* 0.97 0.81 – 1.16 0.76 
Systolic blood pressure at baseline (per 1 SD increase)* 0.88 0.74 – 1.05 0.76 
STEMI 2.96 1.85 – 4.72 <0.001 
Killip Class ≥ 3 1.73 0.59 – 5.05 0.31 
C statistics: 0.70 
*SDs for heart rate and systolic blood pressure are 17.5 b.p.m and 23.1 mmHg 
IHD indicates ischemic heart disease; STEMI, ST-segment elevation myocardial infarction; SD, standard 
deviation  
Impact of oncurrent preprocedural treatments and angiographic characteristics  
On secondary analyses (Table 5), administration of pre-procedural unfractioned heparin, 
showed a strong inverse predictive value in terms of post-PCI TIMI flow and no-reflow 
phenomenon. Similarly, a 600 mg loading dose of clopidogrel showed a trend associated with 
a reduction in the likehood of no-reflow. The presence of a mutivessel coronary disease, 
stenosis ≥ 50% of the right coronary artery and impaired pre-procedural TIMI blood flow 
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grade predicted the development of no-reflow phenomenon. The areas under the under the 
receiver-operator characteristic curves for the models ranged from 0.70 to 0.79 indicating 
good discriminatory powers (Table 5).  
Table 5. Therapeutic and angiographic factors associated with no-reflow phenomenon in 
multivariate analysis  
Variable OR (95% CI) P Value C statistics 
Model 1    
Aspirin  0.83 (0.11 – 6.25) 0.82 0.70 
Model 2    
Clopidogrel 600 mg vs. 300 mg 0.61 (0.37 – 1.00) 0.05 0.72 
Model 3    
UFH 0.65 (0.43 – 0.99) 0.04 0.70 
Model 4    
Enoxaparin 1.47 (0.98 – 2.20) 0.06 0.70 
Model 5    
Mutivessel disease  2.13 (1.29 – 3.50) 0.003 0.74 
Model 6    
LAD stenosis ≥ 50% 1.21 (0.76 – 1.93) 0.40 0.72 
Model 7    
RCA stenosis ≥ 50%  1.81 (1.08 – 3.01) 0.02 0.73 
Model 8    
Baseline TIMI flow grade 0-1 vs. 2-3 7.67 (3.30 – 17.81) <0.001 0.79 
LAD indicates left descending artery; RCA, right coronary artery, TIMI, Thrombolysis In Myocardial Infarction; 
UFH, unfractioned heparin.  
The following covariates are sequentially included in the adjusted models as dummy variables: Model 1 as in 
Table 4 with the inclusion of aspirin. Model 2 as in Table 4 with the inclusion of clopidogrel. Model 3 as in 
Table 4 with the inclusion of UFH. Model 4 as in Table 4 with the inclusion of enoxaparin. Model 5 as in Table 
4 with the inclusion of multivessel coronary disease. Model 6 and 7 as in Table 4 with the inclusion of coronary 
stenosis severity. Model 8 as in Table 4 with the inclusion of baseline TIMI flow grade 0-1.  
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DISCUSSION 
In the present study patients developing no-reflow during PCI in the clinical setting of ACS 
had over four-fold higher risk of in-hospital mortality as compared with those in which 
patency and flow was restored successfully. These results did not change after adjusting for 
baseline characteristic and clinical presentation. No-reflow phenomenon occurred more 
frequently in patients presenting with STEMI as index event, and in patients with multivessel 
coronary artery disease. Yet, the major strength of the study is its therapeutic findings: pre-
procedural administration of unfractioned heparin and/or a 600 mg loading dose of 
clopidogrel was associated with approximately 35% reduction in the incidence of no-reflow.  
Previous studies on the incidence of no-reflow phenomenon   
In the present study the incidence of no-reflow was 2.1%. The reported incidence of no-
reflow varies across studies ranging from 0.6% to 42% [2-7]. Possible reasons might be that 
the incidence of no-reflow depends on the clinical setting and the definitions used. No-reflow 
is more common in patients presenting with myocardial infarction. Among 291,380 acute MI 
patients undergoing PCI, enrolled in the National Cardiovascular Data Registry (NCDR), the 
incidence of no-reflow, defined as TIMI blood flow grade 0-1 was 2.8% [3]. However, the 
definition of no-reflow in this study included also those patients having mechanical 
complications of PCI, which makes difficult a comparison with our findings. Other 
observations have shown that no-reflow is more common in STEMI patients undergoing 
primary PCI than in those performing elective PCI. In a large study among 1,406 STEMI 
patients undergoing primary PCI, no-reflow was identified in 29% of these patients [4]. In a 
subgroup post-hoc analysis of the Harmonizing Outcomes With Revascularization and Stents 
in Acute Myocardial Infarction (HORIZONS-AMI) trial, no-reflow occurred in 10.2% of 
patients [5].  
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The current study analyzed all ACS patients undergoing PCI regardless of timing of 
procedure and clinical presentation. A similar study reported an incidence of no-reflow of 
3.1% [6]. The higher incidence of no-reflow in previous observations as compared with our 
findings (3.1% versus 2.1%) could be explained by the elapsed time between the two studies, 
over a decade. Prior studies could not account for large improvements in adjunctive therapies 
and catheter based interventions.  
Impact of no-reflow phenomenon on prognosis 
In the present study the risk of short-term mortality was 4.6-fold higher in patients who 
developed no-reflow phenomenon during PCI. Similarly, more than 3-fold increase in the risk 
of in-hospital mortality was reported in the NCDR registry. In the current study older age, 
diabetes, STEMI and higher Killip Classes had the strongest associations with mortality by 
multivariate analysis. All of these factors have been recognized as determinants of poor 
outcome in patients with ACS. Elderly, diabetic and STEMI patients have a greater 
atherosclerotic plaque burden, which makes them at greater risk of adverse events [25, 26]. In 
acute heart failure patients’ reduced myocardial contractility may result in reduced cardiac 
output, which in turn may further impair coronary blood flow [27, 28]. Several studies have 
shown that no-reflow during PCI impacts significantly also long term prognosis [5, 29]. In 
one small study mortality rates in no-reflow patients increased progressively over a 6-month 
follow-up period [29]. Other studies have reported more than two-fold increase for 
cardiovascular mortality in no-reflow patients at 5-year follow-up [5]. This matter is of 
concern considering that no-reflow consists in an acute and transient reduction of coronary 
flow. Previous studies have shown strong associations of no-reflow with considerable 
decrease of myocardial salvage, larger infarct size and reduced left ventricular function [30]. 
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In the present study infarct size as measured by creatine kinase - MB fraction or troponin 
levels was higher in patients who developed no-reflow.  
Impact of in-hospital complications 
Life threatening ventricular arrhythmias such as ventricular tachycardia and/or ventricular 
fibrillation occurred more frequently in patients who developed no-reflow (2.3% versus 
1.2%), which is in keeping with the observation  that higher rates of reperfusion arrhythmias 
are related to continuing ischemia due to microvascular damage [31, 32]. Previous studies 
have also shown that coronary patency is associated with an increase on the incidence of 
accelerated idioventricular rhythm and ventricular tachycardia and have reported a positive 
correlation between frequency of ventricular arrhythmias and biomarkers of necrosis [33, 34].  
Although, infrequent, stroke is a critical complication of ACS, that occurs in 0.7 - 2.5% of 
patients [35, 36]. In the current study the overall rates of stroke were 0.3%. This lower 
incidence in our cohort could be explained by the fact that most of the previous studies have 
assessed the incidence of stroke in combination with fibrinolytic or antithrombotic therapy, 
which is a well-recognized cause of stroke. Interestingly, in the current study the rates of 
stroke following PCI were higher in no-reflow patients group, which may be associated with 
the fact that the rates of thrombus aspiration were relatively low in our cohort (3.4%).  In 
addition, PCI with thrombus aspiration was performed more frequently in the no-reflow 
group, which is concordant with recent data from the Routine Aspiration Thrombectomy with 
PCI versus PCI Alone in Patients with STEMI (TOTAL) Trial. The trial reported two fold 
increase in the rates of stroke within 30 days follow up in the routine thrombectomy arm [37].  
Main predictors of no-reflow  
In the ISACS – TC clinical and demographic predictors of no –reflow were older age STEMI 
as index event and hypercholesterolemia. Elderly, and STEMI patients carries a greater 
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thrombus and atherosclerotic plaque burden. Indeed, patients in the ISACS – TC, in whom 
occurred no-reflow had lower degrees of pre-procedural TIMI blood flow grade (93.9% 
versus 57.4%). On multivariate analysis, no-reflow phenomenon was more than 7 – fold 
higher in patients who had a baseline TIMI blood flow grade 0 - 1. This finding could be 
related to higher rates of STEMI as index event, high-burden thrombus formation and greater 
lesion complexity. Several reports have shown that the incidence of distal embolization is 
higher in patients with greater thrombus burden. Thrombus features related to no - reflow 
have been documented to be, large thrombus with cut-off pattern occlusion pattern, presence 
of accumulated thrombus or floating thrombus proximal to occlusion [38]. Other studies have 
reported that high risk coronary lesions (American Heart Association/American College of 
Cardiology class C lesions), longer lesions and bifurcated lesions are associated with no-
reflow phenomenon [3]. In the current cohort, there were no differences with respect to mean 
lesion length or bifurcated lesions, however presence of multivessel coronary disease was a 
predictor of no reflow. A recent study linked no-reflow phenomenon with higher SYNTAX 
scores. Although in this study multivessel coronary disease was not directly associated with 
no-reflow phenomenon, it should be noted that patients having higher SYNTAX scores had 
higher also rates of multivessel coronary disease [39]. Multivessel coronary disease is 
incorporated in the SYNTAX score [40] and therefore may have a role in the prediction of no-
reflow phenomenon.  
Hypercholesterolemia is well recognized risk factors for microvascular dysfunction. It may 
contribute, at least partially, in the pathogenesis of no-reflow. Hypercholesterolemia has been 
found to be associated with reperfusion injury oxidative stress and consequent no-reflow in 
rabbits [41]. Our observations are in agreement. Hypercholesterolemia therefore may mediate 
no-reflow through systemic inflammatory response, platelet/endothelial activation, micro-
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vascular vasoconstriction, myocardial oedema, oxygen-derived free radicals and calcium 
overload.  
Benefits of unfractioned heparin  
Lack of randomized controlled clinical trials remains a limitation to give specific guidelines. 
No-reflow can still occur even under the best provided care, which emphasizes the need for 
more specific medical treatments. In the current study pre-procedural administration of 
unfractioned heparin was associated with a 35% decrease in the incidence of no-reflow during 
PCI. Because platelet thrombin and fibrin plugging is an important contributor to the 
pathogenesis of the no-reflow phenomenon, unfractioned heparin may be beneficial in the 
prevention of the no-reflow phenomenon during percutaneous coronary intervention. Studies 
have shown that unfractioned heparin is beneficial in reducing the dynamic process of 
thrombus formation and propagation. Many of patients experiencing no reflow presented late 
from symptom onset. For late treated patients more thrombin-specific agents are needed, as 
fresh thrombi have the highest proportion of platelets, while the proportion of fibrin fibbers 
increases over time, as the level of thrombin increases [42]. Under these circumstances, 
unfractioned heparin is particularly beneficial as it is effective in modulating the contact 
activation pathway by inactivating thrombin, through an antithrombin-dependent mechanism 
[43]. Unfractioned heparin also inhibits thrombin-induced activation of platelets and the 
resulting formation of an insoluble fibrin network [43]. Accordingly our data have showed 
that enoxaparin is not effective in preventing the no reflow. The shorter chain length of this 
drug enoxaparin is unable to block the contact activation pathway and, therefore, has a 
reduced ability to inhibit thrombin. Low-molecular-weight fractions of heparin react less with 
platelets than high-molecular-weight fractions [42]. Few controlled studies have confirmed 
the beneficial effects of unfractioned heparin in the setting of no reflow. However, these 
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considerations are also, supported by recent findings from randomized trials that confirmed 
that unfractioned heparin is at least as effective and safe as enoxaparin in primary PCI for 
STEMI [44].  
Benefits of clopidogrel 
As previously mentioned, platelet and fibrin plugging is an important contributor to the 
pathogenesis of the no-reflow phenomenon. Clopidogrel may be, therefore, beneficial in the 
prevention of the no-reflow phenomenon during percutaneous coronary intervention as well. 
In our study, patients receiving 600-mg loading dose of clopidogrel showed a significantly 
lower incidence of no reflow compared to those treated with  300-mg. Improved 30-day 
clinical outcomes have been recently shown with clopidogrel 600 mg in a small, 
nonrandomized study of patients with STEMI who underwent primary PCI compared to a 
300-mg dose [45]. These data are concordant with previous observations on the effects of a 
glycoprotein IIb/IIIa blocker (abciximab) on angiographic no-reflow phenomenon [46] 
Patients who received abciximab before coronary intervention had significantly more TIMI 
blood flow grade 3 compared with patients who received placebo. It is therefore suggested 
that antiplatelet therapy not only result in better epicardial blood flow but also lead to less no-
reflow phenomenon and better flow of the coronary microcirculation.  
Bleeding 
Although the present study supports the concept of the pre-procedural administration of UFH 
and 600 mg loading of clopidogrel in patients with ACS undergoing PCI is beneficial in terms 
of reduction of incidence of no-reflow, concerns about bleeding with antithrombotic therapy 
are still relevant to clinical practice. In the current study, risk of major bleeding was 
insignificant and did not differ between patients groups (no-reflow: 0.8% versus 1.4%, 
P=0.58). 
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Strengths of the study  
This study has several strengths. First, patients having mechanical complications, such abrupt 
vessel closure, dissection, perforation, thrombus of the original target lesion, or epicardial 
spasm during PCI were not included in the no-reflow group. Also patients in whom the 
procedural success was not achieved were excluded from the no-reflow definition. Second, 
the definition of no-reflow varies considerably across studies. Many studies defined no-reflow 
phenomenon as post-procedural TIMI blood flow grade ≤ 2. The present study defined no-
reflow as post-procedural TIMI blood flow grade 0 – 1 and not included in the no-reflow 
group patients with post-procedural TIMI blood flow grade 2, an angiographic condition 
generally referred to as coronary slow-flow. Third, in the current study the independent 
relationships between medications and the incidence of no-reflow were estimated introducing 
in the models pre-procedural medications such as unfractioned heparin and clopidogrel. 
Glycoprotein IIb/IIIa inhibitors may have been selectively administered during PCI and 
therefore were not included in the models. Finally, patient groups were comparable with 
respect to the majority of demographic, baseline and angiographic characteristics enabling to 
control the incidence of no-reflow for pre-procedural medications, clinical and angiographic 
severity of illness, which may be persistent important confounders.  
Study limitations 
There are several limitations. First, although patient groups were comparable, bias may still 
be present. The present study cannot rule out that unmeasured confounders may have affected 
the results. Second, information about intracoronary vasodilators such as adenosine, 
nitroglycerin, sodium nitroprusside, verapamil, dialtiazem or nicoradil, which have been 
shown to be effective in the treatment of no-reflow was not available. Third, relatively few 
patients had information on whether they had distal embolization and therefore were not 
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excluded from the study. However, there is strong evidence that distal embolization of the 
plaque/thrombus following balloon inflation is an important factor in the development of no-
reflow [8, 47]. Moreover angiographically evident distal embolization occurs in 
approximately 15% of patients [48]. Thus the choice was not to exclude patients with full 
records on distal embolization as this would have underrepresent the incidence of no-reflow. 
Finally, the observational nature of this study do not control for unmeasured confounders. 
However, results of a registry are valuable as they allow studying real-world practice patterns.     
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CONCLUSIONS 
 
No-reflow during PCI is a strong independent predictor of in-hospital mortality. Pre-
procedural administration of 600 mg loading dose of clopidogrel and unfractioned heparin in 
this study is associated with reduced incidence of no-reflow. Aggressive antithrombotic 
strategies could be considered in order to reduce the no-reflow incidence and improve 
outcomes. Despite these observations, further prospective larger studies remain necessary to 
confirm the results. 
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